Effect of High Intensity Exercise Rehabilitation on Liver Function and Insulin Sensitivity in Patients With MASLD

Launched by UNIVERSITY GHENT · Apr 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different types of exercise can improve liver health and insulin sensitivity in people with a condition called metabolic dysfunction-associated steatotic liver disease (MASLD), which is a common liver disease often linked to obesity. The researchers want to compare two forms of exercise: one that includes regular strength training combined with aerobic exercise, and another that adds high-intensity interval training (HIIT) to strength training. The main goal is to see how these exercises affect the amount of fat in the liver.

To participate in this trial, you need to be between 18 and 75 years old and have been diagnosed with MASLD through ultrasound or other tests. It's important that you don't have serious liver damage or other major health issues that would prevent you from safely participating in the exercise program. If you join, you can expect to take part in a structured exercise routine while being monitored by healthcare professionals. This study is currently looking for volunteers, so it could be a great opportunity to contribute to research that may help others with similar health challenges in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with MASLD by ultrasound, CAP and/or biopsy
• • Age between 18 and 75 years old
• • No significant liver fibrosis (Fibroscan \< 7.5 kPa; if it is between \>7.5 and \<10, there must be absence of liver fibrosis in the biopsy)
• Exclusion Criteria:
• • Presence of other liver diseases that may contribute to the clinical presentation in the patient
• • Severe cardiovascular, orthopedic, physical or other illnesses that make it impossible to participate in the study's exercise rehabilitation program or where safety cannot be guaranteed
• • Pregnancy
• • Pharmacological treatment that directly affects MASLD (e.g. GLP-1 analogues)
• • A change in medication in the last three months before the study that affects metabolic disease stability